OBJECTIVE: To examine the relationship between HIV-1 antigenic load (plasma RNA copies/mL) and broad HIV-1 neutralizing antibody activity. METHODS: Plasma from 120 HIV-1-infected patients, including HIV-1 natural viral suppressors (similar to elite controllers), was tested for neutralization against 15 Tier 1/Tier 2 HIV-1 pseudoviruses. Broad HIV-1 neutralizing antibody activity was confirmed with immunoglobulin G and heterlogous clade testing (18 pseudoviruses from Clades A, C, and CRF02_AG). Statistical analysis was performed to determine factors associated with broad HIV-1 neutralizing antibody activity. RESULTS: Ten individuals with broad HIV-1 neutralizing antibody activity were identified. These individuals had a median CD4 count of 589 cells per microliter (range 202-927), 1611 HIV-1 RNA copies per milliliter (range 110-8964), and 13 years since HIV diagnosis (range 1-22). There was a significant correlation between the presence of broadly neutralizing antibodies in those with HIV-1 RNA between 100 and 10,000 copies per milliliter compared with those <100 or >10,000 copies per milliliter (P = 0.0003 and 0.0245, respectively). Individuals with HIV-1 RNA 100-10,000 copies per milliliter had a higher number of Tier 2 viruses neutralized compared with the <100 or >10,000 copies per milliliter groups (P ≤ 0.0001 and P = 0.076, respectively). Male sex was associated with broad HIV-1 neutralizing antibody activity (P = 0.016). CONCLUSIONS: These results indicate that low but persistent HIV antigen expression correlates with broad HIV-1 neutralizing antibody activity. At higher levels of plasma viremia, neutralization titers were diminished. Conversely, at lower levels, there seems to be insufficient antigen stimulation to maintain high neutralization titers. These findings may have important implications in furthering the understanding of the humoral response to HIV infection.
OBJECTIVE: To examine the relationship between HIV-1 antigenic load (plasma RNA copies/mL) and broad HIV-1 neutralizing antibody activity. METHODS: Plasma from 120 HIV-1-infectedpatients, including HIV-1 natural viral suppressors (similar to elite controllers), was tested for neutralization against 15 Tier 1/Tier 2 HIV-1 pseudoviruses. Broad HIV-1 neutralizing antibody activity was confirmed with immunoglobulin G and heterlogous clade testing (18 pseudoviruses from Clades A, C, and CRF02_AG). Statistical analysis was performed to determine factors associated with broad HIV-1 neutralizing antibody activity. RESULTS: Ten individuals with broad HIV-1 neutralizing antibody activity were identified. These individuals had a median CD4 count of 589 cells per microliter (range 202-927), 1611 HIV-1 RNA copies per milliliter (range 110-8964), and 13 years since HIV diagnosis (range 1-22). There was a significant correlation between the presence of broadly neutralizing antibodies in those with HIV-1 RNA between 100 and 10,000 copies per milliliter compared with those <100 or >10,000 copies per milliliter (P = 0.0003 and 0.0245, respectively). Individuals with HIV-1 RNA 100-10,000 copies per milliliter had a higher number of Tier 2 viruses neutralized compared with the <100 or >10,000 copies per milliliter groups (P ≤ 0.0001 and P = 0.076, respectively). Male sex was associated with broad HIV-1 neutralizing antibody activity (P = 0.016). CONCLUSIONS: These results indicate that low but persistent HIV antigen expression correlates with broad HIV-1 neutralizing antibody activity. At higher levels of plasma viremia, neutralization titers were diminished. Conversely, at lower levels, there seems to be insufficient antigen stimulation to maintain high neutralization titers. These findings may have important implications in furthering the understanding of the humoral response to HIV infection.
Authors: Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht Journal: J Virol Date: 2006-06 Impact factor: 5.103
Authors: Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano Journal: J Virol Date: 2006-05 Impact factor: 5.103
Authors: T Harrer; E Harrer; S A Kalams; T Elbeik; S I Staprans; M B Feinberg; Y Cao; D D Ho; T Yilma; A M Caliendo; R P Johnson; S P Buchbinder; B D Walker Journal: AIDS Res Hum Retroviruses Date: 1996-05-01 Impact factor: 2.205
Authors: Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori Journal: J Virol Date: 2005-08 Impact factor: 5.103
Authors: A K Pilgrim; G Pantaleo; O J Cohen; L M Fink; J Y Zhou; J T Zhou; D P Bolognesi; A S Fauci; D C Montefiori Journal: J Infect Dis Date: 1997-10 Impact factor: 5.226
Authors: E Barker; C E Mackewicz; G Reyes-Terán; A Sato; S A Stranford; S H Fujimura; C Christopherson; S Y Chang; J A Levy Journal: Blood Date: 1998-11-01 Impact factor: 22.113
Authors: Anne Piantadosi; Dana Panteleeff; Catherine A Blish; Jared M Baeten; Walter Jaoko; R Scott McClelland; Julie Overbaugh Journal: J Virol Date: 2009-07-29 Impact factor: 5.103
Authors: Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico Journal: J Virol Date: 2012-02-29 Impact factor: 5.103
Authors: Mohammad Mohseni Sajadi; Amir Dashti; Zahra Rikhtegaran Tehrani; William D Tolbert; Michael S Seaman; Xin Ouyang; Neelakshi Gohain; Marzena Pazgier; Dongkyoon Kim; Guy Cavet; Jean Yared; Robert R Redfield; George K Lewis; Anthony L DeVico Journal: Cell Date: 2018-05-03 Impact factor: 41.582
Authors: Carolina B Ferreira; Alberto Merino-Mansilla; Anuska Llano; Ignacio Pérez; Isabel Crespo; Laia Llinas; Felipe Garcia; Jose M Gatell; Eloisa Yuste; Victor Sanchez-Merino Journal: J Virol Date: 2013-09-04 Impact factor: 5.103
Authors: Jacques Thèze; Lisa A Chakrabarti; Benoît Vingert; Filippos Porichis; Daniel E Kaufmann Journal: Clin Immunol Date: 2011-08-04 Impact factor: 3.969
Authors: Yongjun Guan; Marzena Pazgier; Mohammad M Sajadi; Roberta Kamin-Lewis; Salma Al-Darmarki; Robin Flinko; Elena Lovo; Xueji Wu; James E Robinson; Michael S Seaman; Timothy R Fouts; Robert C Gallo; Anthony L DeVico; George K Lewis Journal: Proc Natl Acad Sci U S A Date: 2012-12-13 Impact factor: 11.205
Authors: Clarisa M Buckner; Lela Kardava; Xiaozhen Zhang; Kathleen Gittens; J Shawn Justement; Colin Kovacs; Adrian B McDermott; Yuxing Li; Mohammad M Sajadi; Tae-Wook Chun; Anthony S Fauci; Susan Moir Journal: J Infect Dis Date: 2016-04-27 Impact factor: 5.226